NCT00000721View on ClinicalTrials.gov

An Escalating Dose Tolerance Trial of BG8962 (rCD4) in Patients Who Are HIV Antibody Positive

PHASE1CompletedINTERVENTIONAL
Enrollment

85

Participants

Timeline

Start Date

Not specified

Study Completion Date

March 31, 1991

Conditions
HIV Infections
Interventions
DRUG

CD4 Antigens

Trial Locations (1)

943055107

Stanford CRS, Palo Alto

Sponsors

Collaborators (1)

Biogen
All Listed Sponsors
collaborator

Biogen

INDUSTRY

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH